Nuvalent, Inc. (NUVL)

Market Cap	7.70B
Revenue (ttm)	n/a
Net Income (ttm)	-381.44M
Shares Out	72.71M
EPS (ttm)	-5.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,218,748
Open	106.95
Previous Close	108.01
Day's Range	105.64 - 109.78
52-Week Range	55.54 - 112.88
Beta	1.31
Analysts	Strong Buy
Price Target	133.85 (+26.42%)
Earnings Date	Oct 30, 2025

About NUVL

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Ph...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 29, 2021
• Employees: 142
• Stock Exchange: NASDAQ
• Ticker Symbol: NUVL
• Website: https://www.nuvalent.com

Analyst Summary

According to 13 analysts, the average rating for NUVL stock is "Strong Buy." The 12-month stock price target is $133.85, which is an increase of 26.42% from the latest price.

Price Target

$133.85

(26.42% upside)

Analyst Consensus: Strong Buy